and epithelial cells through omission of the Wnt agonist R-spondin-1 and inclusion of other factors. The resultant protocol allowed successful derivation of organoids from eight different patients with PLC, spanning the HCC, CC and CHC tumor subtypes. These PLC organoids preserved the histology and mutational spectrum of the original tumors, even after long-term passaging, and exhibited in vivo tumorigenicity upon subcutaneous transplantation into mice. Broutier et al. 5 They demonstrate the feasibility of using the resultant organois, termed 'tumoroids' , to model tumor subtypes and for anticancer drug discovery ( Fig. 1) .
Broutier et al. 5 built on previous work demonstrating growth of organoids from clinical tumor biopsies to develop culture models that accurately reflect the histological diversity of PLC. The authors carefully optimized their processing and culture conditions to minimize overgrowth of normal hepatocytes A major goal of cancer precision medicine is to identify the most appropriate treatment modality for the genetic landscape of a patient's tumor. Despite advances in cancer genomic analysis and discovery of druggable targets, a large number of patients do not respond to therapies as predicted, indicating the need for improved models to predict therapeutic outcome 1 . The development of 3D organoid culture methods provides an emerging approach for preclinical studies of cancer therapy, complementing established cancer cell lines and patient-derived xenografts. These miniaturized organoid 'avatars' of a patient's tumor recapitulate the histological and gene expression features of the original tumor and can be genetically characterized, manipulated and expanded, rendering them an attractive model for guiding cancer precision medicine 2 . Organoid models may be particularly applicable to identifying patientspecific drug sensitivities, as is being increasingly demonstrated through treatment of a patient's miniature tumor avatar in a dish with a myriad of drugs to identify the most effective treatment strategy 3, 4 . Applications of organoids to study diverse or rare tumor types, to model premalignant states such as polyposis and to perform anticancer drug discovery are only now being explored.
A recent study in Nature Medicine highlights the use of patient-specific organoid strategies to model cancer therapeutic responses in patientspecific tissue. In this study Broutier et al. 5 used patient tumor biopsy tissue to generate and characterize organoid models of three types of primary liver cancer (PLC): hepatocellular carcinoma (HCC), cholangiocarcinoma (CC) and combined HCC/CC cancer (CHC). tumor, in contrast to long-passaged cancer cell lines. As current organoid strategies begin with limiting amounts of biopsy tissue, in vitro expansion is typically required before therapeutic screening. To reach the ultimate goal of cancer precision medicine, it will be important to accelerate contemporary organoid methods, as in this study, to actionable time frames to allow guidance of treatment choices in real time.
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also carried out comparative gene expression analysis of PLC-derived organoids versus those derived from healthy liver, identifying several genes that were upregulated among the different PLC subtypes, some of which correlated with poor survival. While future validation studies of these genes are needed to accurately define their role in PLC progression, this study demonstrates the feasibility of using organoid models for biomarker discovery. Broutier et al. 5 then tested the sensitivity of the PLC organoid lines to 29 compounds, finding that the ERK1 and ERK2 (ERK1/2) kinase inhibitor SCH772984 repressed in vitro growth of HCC, CC and CHC organoid lines, including some that were resistant to inhibitors targeting BRAF and MEK within the same pathway. Furthermore, SCH772984 inhibited in vivo tumor growth of representative HCC and CC organoids, suggesting that it might have clinical utility as a novel treatment strategy for patients with liver cancer.
As illustrated by this example, organoid technologies are progressively entering the mainstream for cancer biology and translational research. Certainly, organoids allow the creation of in vitro models from rare subtypes of cancer for which cell lines do not exist, such as for liver cancer in the current study, and facilitate the accumulation of sufficient tumor-derived biomass for deep 'omics' study. Importantly, organoids provide a robust method to preserve clinical tumor samples with a high success rate. Furthermore, these organoids represent an early state of the original
Recognition of self-DNA drives cardiac inflammation: why broken hearts fail

Kory J Lavine & Douglas L Mann
Signals that govern immune cells in the heart remain poorly defined. A new report in mice shows that pathways involved in sensing viruses orchestrate monocyte and macrophage activation through recognition of DNA derived from dying cardiomyocytes following myocardial infarction.
For patients who suffer a myocardial infarction, infarct size and the extent of left ventricular (LV) remodeling are both major determinants of disease progression and are both associated with substantially increased mortality. In response to the tissue injury that occurs as a result of myocardial infarction, the innate immune system is robustly activated at the local and systemic levels 1 . Intriguingly, individuals who experience similar extents of injury may display highly variable immune responses. Within this continuum, patients with a greater degree of systemic inflammation following myocardial infraction have increased infarct expansion, LV remodeling and LV systolic dysfunction together with higher mortality rates 2-4 . These observations not only exemplify the prognostic importance of innate immune activation following ischemic myocardial injury, but also suggest that manipulation of innate immune responses may be sufficient to ameliorate tissue damage and improve outcomes.
Previous studies employing human pathological specimens and animal models of myocardial infarction have described the accumulation of myeloid cells, including monocytes, macrophages and neutrophils, within the injured myocardium 5, 6 . While it is well established that neutrophils produce robust inflammatory and oxidative responses and contribute to the development of heart failure, the exact roles of monocytes and macrophages remain areas of active investigation. It is widely accepted that, following ischemic cardiac injury, Ly6C high CCR2 + monocytes infiltrate the heart, replace resident cardiac macrophage subsets and differentiate into monocytederived macrophages that predominately function to stimulate proinflammatory responses, resulting in collateral tissue damage and contributing to cardiac dysfunction 7 . Less is known about how these cells are recruited and activated once they enter the infarcted heart. In this issue, King et al. 8 report in mice that recognition of self-DNA derived from dying cardiomyocytes constitutes an important signal orchestrating activation of monocytes and macrophages in the infarcted heart.
Recently, it has emerged that cells that are injured or that undergo cell death through necrosis, necroptosis or aborted apoptosis release intracellular signaling molecules with potent effects on immune cells 9 . Dying or injured cardiomyocytes release an array of signals collectively referred to as dangerassociated molecular patterns (DAMPs) that encompass a variety of mediators, including nucleotides, bioactive lipids, extracellular matrix fragments and lectins 10 . The majority of DAMPs are recognized by pattern-recognition receptors (PRRs), which are expressed on leukocytes, as well as on cells residing within the myocardium. PRRs are well known for their roles in recognizing pathogen-derived products referred to as pathogen-associated molecular patterns (PAMPs). Classically, engagement of PRRs results in activation of mononuclear phagocytes and generation of profound inflammation responses aimed at eliminating both pathogens and infected cells. Beyond Tolllike receptors 11 , the exact DAMPs and downstream signaling mechanisms that coordinate monocyte and macrophage activation are largely unknown.
